| 纯度 | >96%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TFF2 |
| Uniprot No | Q03403 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-129aa |
| 氨基酸序列 | EKPSPCQCSRLSPHNRTNCGFPGITSDQCFDNGCCFDSSVTGVPWCFHPL PKQESDQCVMEVSDRRNCGYPGISPEECASRKCCFSNFIFEVPWCFFPKS VEDCHY |
| 预测分子量 | 12 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TFF2重组蛋白的3篇示例参考文献，包含文献名称、作者及摘要概括：
---
1. **文献名称**：*Recombinant TFF2 Enhances Gastric Mucosal Healing in a Rat Ulcer Model*
**作者**：Smith A, et al.
**摘要**：研究重组人TFF2蛋白在大鼠胃溃疡模型中的治疗效果，证明其通过促进上皮细胞迁移和抑制炎症加速黏膜修复。
2. **文献名称**：*Anti-inflammatory Effects of Recombinant TFF2 in Colitis*
**作者**：Lee B, Kim C.
**摘要**：探讨重组TFF2在小鼠结肠炎模型中的作用，发现其通过调节NF-κB通路减少促炎因子表达，缓解肠道炎症。
3. **文献名称**：*Expression and Purification of Functional TFF2 in E. coli*
**作者**：Zhang X, et al.
**摘要**：报道一种高效重组表达TFF2的方法，利用大肠杆菌系统优化表达条件，获得具有生物活性的TFF2蛋白。
---
*注：以上文献信息为示例，实际引用时建议通过PubMed或Web of Science等数据库检索最新研究。*
TFF2 (trefoil factor family 2), a small secretory protein belonging to the trefoil factor family (TFF1. TFF2. TFF3), plays critical roles in mucosal protection and repair. Characterized by a conserved trefoil motif formed by six cysteine residues forming three disulfide bonds, TFF2 is notably resistant to protease degradation and acidic environments, making it vital in gastrointestinal homeostasis. It is primarily expressed in the gastric mucosa, secreted by mucous neck cells of the stomach and Brunner’s glands in the duodenum.
Biologically, TFF2 promotes epithelial restitution by enhancing cell migration, supporting mucus layer formation, and maintaining barrier integrity. It also modulates immune responses, influencing cytokines and immune cell activity, which is relevant in inflammatory conditions like gastritis or inflammatory bowel disease (IBD). Paradoxically, TFF2 exhibits dual roles in cancer—acting as a tumor suppressor in early stages but potentially promoting progression in advanced cancers, depending on context and microenvironment.
Recombinant TFF2 is produced via expression systems (e.g., E. coli, yeast, mammalian cells), with mammalian systems preserving post-translational modifications like glycosylation. Its therapeutic potential is explored in mucosal injury repair, chronic inflammation, and cancer. Challenges include understanding context-dependent signaling mechanisms and optimizing delivery for clinical use. Current research focuses on clarifying its molecular pathways and advancing preclinical models to harness its reparative and immunomodulatory properties effectively.
×
